The stock of Plus Therapeutics Inc (NASDAQ: PSTV) has increased by 4.44 when compared to last closing price of 1.80.Despite this, the company has seen a gain of 13.25% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-05 that Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2023 Earnings Conference Call March 5, 2024 5:00 PM ET Company Participants Marc Hedrick – President and CEO Andrew Sims – CFO Norman LaFrance – CMO Conference Call Participants Justin Walsh – Jones Trading Sean Lee – H.C. Wainwright Edward Woo – Ascendiant Capital Operator Good afternoon, ladies and gentlemen.
Is It Worth Investing in Plus Therapeutics Inc (NASDAQ: PSTV) Right Now?
Company’s 36-month beta value is 0.51.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PSTV is 4.21M, and currently, short sellers hold a 1.10% ratio of that floaft. The average trading volume of PSTV on May 06, 2024 was 30.13K shares.
PSTV’s Market Performance
The stock of Plus Therapeutics Inc (PSTV) has seen a 13.25% increase in the past week, with a -0.01% drop in the past month, and a -0.53% fall in the past quarter. The volatility ratio for the week is 4.53%, and the volatility levels for the past 30 days are at 6.63% for PSTV. The simple moving average for the last 20 days is 7.79% for PSTV’s stock, with a simple moving average of 0.88% for the last 200 days.
Analysts’ Opinion of PSTV
Many brokerage firms have already submitted their reports for PSTV stocks, with Ladenburg Thalmann repeating the rating for PSTV by listing it as a “Buy.” The predicted price for PSTV in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on January 25, 2021 of the previous year 2021.
Maxim Group, on the other hand, stated in their research note that they expect to see PSTV reach a price target of $6. The rating they have provided for PSTV stocks is “Buy” according to the report published on October 16th, 2020.
PSTV Trading at 3.88% from the 50-Day Moving Average
After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.07% of loss for the given period.
Volatility was left at 6.63%, however, over the last 30 days, the volatility rate increased by 4.53%, as shares sank -1.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.53% lower at present.
During the last 5 trading sessions, PSTV rose by +12.65%, which changed the moving average for the period of 200-days by -10.97% in comparison to the 20-day moving average, which settled at $1.7431. In addition, Plus Therapeutics Inc saw 7.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PSTV starting from HEDRICK MARC H, who sale 2,068 shares at the price of $1.96 back on Nov 20 ’23. After this action, HEDRICK MARC H now owns 170 shares of Plus Therapeutics Inc, valued at $4,053 using the latest closing price.
Lenk Robert P, the Director of Plus Therapeutics Inc, purchase 1,000 shares at $1.95 during a trade that took place back on Nov 16 ’23, which means that Lenk Robert P is holding 25,160 shares at $1,950 based on the most recent closing price.
Stock Fundamentals for PSTV
Current profitability levels for the company are sitting at:
- -2.71 for the present operating margin
- 0.85 for the gross margin
The net margin for Plus Therapeutics Inc stands at -2.71. The total capital return value is set at -20.15. Equity return is now at value -522.50, with -75.54 for asset returns.
Based on Plus Therapeutics Inc (PSTV), the company’s capital structure generated 1.48 points at debt to capital in total, while cash flow to debt ratio is standing at -3.07. The debt to equity ratio resting at -3.1. The interest coverage ratio of the stock is -33.72.
Currently, EBITDA for the company is -12.58 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.92.
Conclusion
In a nutshell, Plus Therapeutics Inc (PSTV) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
